Cargando…
Liquid biopsy for disease monitoring after anti‐CD19 chimeric antigen receptor T cell in diffuse large B‐cell lymphoma
OBJECTIVES: Chimeric antigen receptor T cells (CARTs) against CD19 antigen represent an effective therapy for relapsed/refractory diffuse large B‐cell lymphoma (rrDLBCL). There is no diagnostic test able to predict which patients with residual disease will relapse from those that will reach a delaye...
Autores principales: | Maluquer, Clara, Bellosillo, Beatriz, Mussetti, Alberto, Domingo‐Domènech, Eva, Parody, Rocío, Fernández‐Ibarrondo, Lierni, Velasco, Roser, Moreno‐González, Gabriel, Sanz, Gabriela, Cortés, Montserrat, Sureda, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176123/ https://www.ncbi.nlm.nih.gov/pubmed/35846093 http://dx.doi.org/10.1002/jha2.131 |
Ejemplares similares
-
Is Post-Transplant Cyclophosphamide the New Methotrexate?
por: Mussetti, Alberto, et al.
Publicado: (2021) -
CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?
por: Velasco, Roser, et al.
Publicado: (2023) -
The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting
por: Condom, Maria, et al.
Publicado: (2021) -
Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy
por: Velasco, Roser, et al.
Publicado: (2021) -
Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: A single-center experience
por: Salas, Maria Queralt, et al.
Publicado: (2022)